|
|
Post by harryx1 on May 19, 2017 8:51:07 GMT -5
|
|
|
|
Post by centralcoastinvestor on May 19, 2017 9:34:46 GMT -5
This is why Afrezza will win in the long run. Tell me what other medications have such passionate volunteer advocates.
|
|
|
|
Post by boca1girl on May 19, 2017 10:51:06 GMT -5
Very good article. The only thing I was disappointed in was..."It's not better. It's different."
Dr. Howard Lippes, a Williamsville endocrinologist, assistant clinical professor with the University at Buffalo medical school and owner of R&B Medical Group, prescribes the inhalable drug to about 15 to 20 percent of his Type 1 adult diabetic patients.
Some use it regularly, others intermittently "to correct high glucose," he said. "There are pros and cons. It's not better. It's different."
|
|
|
|
Post by brotherm1 on May 19, 2017 11:44:22 GMT -5
"Dr. Howard Lippes, a Williamsville endocrinologist, assistant clinical professor with the University at Buffalo medical school and owner of R&B Medical Group, prescribes the inhalable drug to about 15 to 20 percent of his Type 1 adult diabetic patients."
If all docs in the US would prescribe Afrezza to 15% of their clients, we would have 150,000 of our 1 million type one adults using it. Worlwide at that rate for type ones we would have about 6 million on Afrezza
|
|
|
|
Post by mnholdem on May 19, 2017 12:42:06 GMT -5
I have no doubt that within the next few years, most doctors will be saying, "Afrezza is better".
|
|
|
|
Post by ilovekauai on May 19, 2017 12:59:59 GMT -5
Aloha! Just woke up out here. What cheerful a script count & other news to discover. Go MNKD, go Afrezza!! Yay! Have a great weekend all true Longs!
|
|
